105 related articles for article (PubMed ID: 17582776)
1. Determination of residual Kryptofix 2.2.2 levels in [18F]-labeled radiopharmaceuticals for human use.
Scott PJ; Kilbourn MR
Appl Radiat Isot; 2007 Dec; 65(12):1359-62. PubMed ID: 17582776
[TBL] [Abstract][Full Text] [Related]
2. A color spot test for the detection of Kryptofix 2.2.2 in [18F]FDG preparations.
Mock BH; Winkle W; Vavrek MT
Nucl Med Biol; 1997 Feb; 24(2):193-5. PubMed ID: 9089712
[TBL] [Abstract][Full Text] [Related]
3. Quantification of Kryptofix 2.2.2 in [18F]fluorine-labelled radiopharmaceuticals by rapid-resolution liquid chromatography.
Lao Y; Yang C; Zou W; Gan M; Chen P; Su W
Nucl Med Commun; 2012 May; 33(5):498-502. PubMed ID: 22330082
[TBL] [Abstract][Full Text] [Related]
4. Thin layer chromatographic detection of kryptofix 2.2.2 in the routine synthesis of [18F]2-fluoro-2-deoxy-D-glucose.
Chaly T; Dahl JR
Int J Rad Appl Instrum B; 1989; 16(4):385-7. PubMed ID: 2777579
[TBL] [Abstract][Full Text] [Related]
5. Elimination of contaminant Kryptofix 2.2.2 in the routine production of 2-[18F]fluoro-2-deoxy-D-glucose.
Moerlein SM; Brodack JW; Siegel BA; Welch MJ
Int J Rad Appl Instrum A; 1989; 40(9):741-3. PubMed ID: 2559062
[TBL] [Abstract][Full Text] [Related]
6. A new precursor for the preparation of 6-[18F]Fluoro-L-m-tyrosine ([18F]FMT): efficient synthesis and comparison of radiolabeling.
VanBrocklin HF; Blagoev M; Hoepping A; O'Neil JP; Klose M; Schubiger PA; Ametamey S
Appl Radiat Isot; 2004 Dec; 61(6):1289-94. PubMed ID: 15388123
[TBL] [Abstract][Full Text] [Related]
7. [Fluorine-18 in radiopharmacy].
de Beco V; Le Bars D; Scherrmann JM
Ann Pharm Fr; 2008 Jan; 66(1):60-5. PubMed ID: 18435989
[TBL] [Abstract][Full Text] [Related]
8. Simultaneous analysis of FDG, ClDG and Kryptofix 2.2.2 in [18F]FDG preparation by high-performance liquid chromatography with UV detection.
Nakao R; Ito T; Yamaguchi M; Suzuki K
Nucl Med Biol; 2008 Feb; 35(2):239-44. PubMed ID: 18312835
[TBL] [Abstract][Full Text] [Related]
9. Development and Successful Validation of Simple and Fast TLC Spot Tests for Determination of Kryptofix® 2.2.2 and Tetrabutylammonium in 18F-Labeled Radiopharmaceuticals.
Kuntzsch M; Lamparter D; Brüggener N; Müller M; Kienzle GJ; Reischl G
Pharmaceuticals (Basel); 2014 May; 7(5):621-33. PubMed ID: 24830987
[TBL] [Abstract][Full Text] [Related]
10. Silicon-based chemistry: an original and efficient one-step approach to [18F]-nucleosides and [18F]-oligonucleotides for PET imaging.
Schulz J; Vimont D; Bordenave T; James D; Escudier JM; Allard M; Szlosek-Pinaud M; Fouquet E
Chemistry; 2011 Mar; 17(11):3096-100. PubMed ID: 21312302
[TBL] [Abstract][Full Text] [Related]
11. A p-[18F]fluoroethoxyphenyl bicyclic nucleoside analogue as a potential positron emission tomography imaging agent for varicella-zoster virus thymidine kinase gene expression.
Chitneni SK; Deroose CM; Balzarini J; Gijsbers R; Celen S; Debyser Z; Mortelmans L; Verbruggen AM; Bormans GM
J Med Chem; 2007 Dec; 50(26):6627-37. PubMed ID: 18047266
[TBL] [Abstract][Full Text] [Related]
12. Radiolabelling diverse positron emission tomography (PET) tracers using a single digital microfluidic reactor chip.
Chen S; Javed MR; Kim HK; Lei J; Lazari M; Shah GJ; van Dam RM; Keng PY; Kim CJ
Lab Chip; 2014 Mar; 14(5):902-10. PubMed ID: 24352530
[TBL] [Abstract][Full Text] [Related]
13. Advances in processes for PET radiotracer synthesis: separation of [¹⁸F]fluoride from enriched [¹⁸O]water.
He P; Haswell SJ; Pamme N; Archibald SJ
Appl Radiat Isot; 2014 Sep; 91():64-70. PubMed ID: 24907685
[TBL] [Abstract][Full Text] [Related]
14. Fully automated [18F]fluorocholine synthesis in the TracerLab MX FDG Coincidence synthesizer.
Kryza D; Tadino V; Filannino MA; Villeret G; Lemoucheux L
Nucl Med Biol; 2008 Feb; 35(2):255-60. PubMed ID: 18312837
[TBL] [Abstract][Full Text] [Related]
15. A fully automated radiosynthesis of [18F]fluoroethyl-diprenorphine on a single module by use of SPE cartridges for preparation of high quality 2-[18F]fluoroethyl tosylate.
Schoultz BW; Reed BJ; Marton J; Willoch F; Henriksen G
Molecules; 2013 Jun; 18(6):7271-8. PubMed ID: 23787515
[TBL] [Abstract][Full Text] [Related]
16. [Current Progresses in Developing PET Radiopharmaceuticals for Patients in the Czech Republic].
Adam J; Demlová R; Řehák Z
Klin Onkol; 2016; 29 Suppl 4():S95-100. PubMed ID: 27846727
[TBL] [Abstract][Full Text] [Related]
17. Synthesis of a new fluorine-18-labeled bexarotene analogue for PET imaging of retinoid X receptor.
Wang M; Davis T; Gao M; Zheng QH
Bioorg Med Chem Lett; 2014 Apr; 24(7):1742-7. PubMed ID: 24602901
[TBL] [Abstract][Full Text] [Related]
18. Pyrazoles as Key Scaffolds for the Development of Fluorine-18-Labeled Radiotracers for Positron Emission Tomography (PET).
Gomes PMO; Silva AMS; Silva VLM
Molecules; 2020 Apr; 25(7):. PubMed ID: 32283680
[TBL] [Abstract][Full Text] [Related]
19. The development of potential new fluorine-18 labelled radiotracers for imaging the GABA(A) receptor.
Jackson A; Guilbert BB; Plant SD; Goggi J; Battle MR; Woodcraft JL; Gaeta A; Jones CL; Bouvet DR; Jones PA; O'Shea DM; Zheng PH; Brown SL; Ewan AL; Trigg W
Bioorg Med Chem Lett; 2013 Feb; 23(3):821-6. PubMed ID: 23265897
[TBL] [Abstract][Full Text] [Related]
20. A spot test for determination of residual TBA levels in
Tanzey SS; Mossine AV; Sowa AR; Torres J; Brooks AF; Sanford MS; Scott PJH
Anal Methods; 2020 Nov; 12(41):5004-5009. PubMed ID: 33000785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
